AL-LAD

AL-LAD, also known as 6-allyl-6-nor-lysergic acid diethylamide, is a hallucinogenic drug, lysergamide and an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL (Tryptamines i Have Known And Loved). AL-LAD is reported as having some subtle experiential differences to LSD (such as the visuals), and also appears to be slightly shorter lasting and slightly more potent.

History

AL-LAD was originally developed by David Nichols along with several LSD analogues, and later reviewed by Alexander Shulgin. The drug was popularised for recreational use in 2012, as part of the progression through the release of chemicals Shulgin discusses and provides syntheses for in his books TiHKAL and PiHKAL. It became increasingly popular among recreational users, via the conduit of its legality and easy access through the Internet. Since then, a few countries such as the UK have moved to illegalise the chemical.

Dosage

Common: 60-160 μg

Strong: 300 μg

Duration

Onset: 45-90 minutes

Duration: 6-8 hours

Effects

In large, AL-LAD is reported as having a very similar effect profile to LSD. However, many subjective differences are noted - a different 'headspace' and slightly different visuals are noted, along with what may be perceived as a slightly 'happier' push.

Harm Reduction

Similar to other psychedelics, and particularly LSD, AL-LAD is relatively safe for recreational use. There are many prevalent misconceptions around psychedelic use which can be safely ignored, but care should still be taken to use the drug responsibly.

General

Avoid driving and operating heavy machinery.

Tolerance

Wait at least four to fourteen days for full effect due to rapid tolerance build, though it's generally advised to wait longer between trips. Ingesting AL-LAD no more than once a month is advised due to the adverse psychological effects of chronic use. The addiction potential of AL-LAD is likely nonexistant, save rare cases in which a person becomes psychologically addicted.

Mental Illness

Psychedelics are known to potentially cause latent mental illness to manifest. Those with mental illnesses should not ingest AL-LAD. Those with a family history of mental illness, including but not limited to depression, schizophrenia, and bipolar should use AL-LAD with extreme caution. AL-LAD may cause dangerous physiological and psychological reactions when used in conjunction with lithium or tricyclic antidepressants.

Legal status

America

Controlled in the United States via the Federal Analog Act, but only if it is intended for human consumption.

United Kingdom

AL-LAD was scheduled as a Class A drug in the UK in June 2014, despite not carrying out any of the usual recommended research on proving any harm is associated with recreational use of the drug.

Links

• The TiHKAL entry for AL-LAD